Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Taylor Hanley - JPMorgan Edouard Mullarky - Guggenheim Securities Operator Good mornin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2022 Earnings Conference Call November 8, 2022 4:00 PM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Edouard Mullarky - Guggenheim Securities Tessa Romero - JPMorgan Chase & Co. Sebastiaan van der Schoot - Kempen ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2022 Results Conference Call August 9, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Robert Burns - HC Wainwright Charles Zhu - Guggenheim Joseph Thome - Cowen & Company Tessa Romero - JP Morgan Mike Ulz - Morgan Stanley William Maughan - Canaccord Genuity Operator Good morning ...

mAbs herapeutics, Inc. Company Presentation August 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and ...

mAbs Therapeutics, Inc. Company Presentation May 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and ob ...

mAbs Therapeutics, Inc. Company Presentation May 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and ob ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2022 Results Conference Call May 10, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Dr. Steen Lisby - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Joseph Thome - Cowen & Company Charles Zhu - Guggenheim Mike Ulz - Morgan Stanley Tessa Romero - JP Morgan Sebastiaan van der Schoot - Kempen Operator G ...

Y-MAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2021 Earnings Conference Call February 25, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Chairman & President Claus Møller - Chief Executive Officer Bo Kruse - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Securities Mike Ulz - Morgan Stanley Joseph Thome - Cowen & Company Tessa Romero - JPMorgan Sebastiaan van der Schoot - Kempen Operator Good day and welcome to the Y-mAbs Therapeutics, ...

mAbs herapeutics, Inc. Company Presentation February 2022 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans an ...